These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1688 related articles for article (PubMed ID: 18543257)

  • 1. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
    J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production.
    Yip KH; Zheng MH; Steer JH; Giardina TM; Han R; Lo SZ; Bakker AJ; Cassady AI; Joyce DA; Xu J
    J Bone Miner Res; 2005 Aug; 20(8):1462-71. PubMed ID: 16007343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
    Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
    Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
    Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
    Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
    Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of reciprocal regulation between the high extracellular calcium and RANKL signal transduction pathways in RAW cell derived osteoclasts.
    Xu J; Wang C; Han R; Pavlos N; Phan T; Steer JH; Bakker AJ; Joyce DA; Zheng MH
    J Cell Physiol; 2005 Feb; 202(2):554-62. PubMed ID: 15389575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival.
    Gingery A; Bradley E; Shaw A; Oursler MJ
    J Cell Biochem; 2003 May; 89(1):165-79. PubMed ID: 12682917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1).
    Kwak HB; Jin HM; Ha H; Kang MJ; Lee SB; Kim HH; Lee ZH
    Biochem Biophys Res Commun; 2005 May; 330(4):1080-6. PubMed ID: 15823554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactive oxygen species mediate RANK signaling in osteoclasts.
    Ha H; Kwak HB; Lee SW; Jin HM; Kim HM; Kim HH; Lee ZH
    Exp Cell Res; 2004 Dec; 301(2):119-27. PubMed ID: 15530848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
    Kwak HB; Lee SW; Li YJ; Kim YA; Han SY; Jhon GJ; Kim HH; Lee ZH
    Biochem Pharmacol; 2004 Apr; 67(7):1239-48. PubMed ID: 15013839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
    Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
    J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.